Welcome to
Sysmex Flow Cytometry Other European Country!

For ordering please make sure you are in your local shop.
If you are from Other European Country then please continue.
Otherwise please go to your country.

Go to my country Continue

Article successfully added.

CyFlow™ CD69 Alexa Fluor™ 647

CyFlow™ CD69 Alexa Fluor™ 647
Antigen: CD69
Alternative Name: AIM, VEA
Clone: FN50
Application: Flow cytometry
Format/Fluorochrome: Alexa Fluor™ 647
Laser: Red
Target Species: Human
Field of Interest: Immunophenotyping
Species of Origin: Mouse
Regulatory Status: RUO
Clonality: monoclonal
Emission Maximum: 665 nm
Excitation Maximum: 650 nm
Isotype: IgG1
Order number: CX180446

For Research Use Only
Not for use in diagnostic or therapeutic procedures.

Quantity 100 tests Volume 0.4 Immunogen Anti-μ-stimulated human B lymphocytes... more
CyFlow™ CD69 Alexa Fluor™ 647
Quantity100 tests
ImmunogenAnti-μ-stimulated human B lymphocytes
Background InformationCD69 (CLEC2C; C-type lectin domain family 2 C or AIM) is one of the earliest inducible cell surface molecules acquired during leukocyte activation. This glycoprotein serves as a lectin-type receptor in lymphocytes, NK cells and platelets; it is involved in lymphocyte proliferation. CD69 expression is counteracted on T cells in the AIDS stage of HIV infection, and may be also predictive for clinical response to chemoimmunotherapy.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.

Specific References

| Knapp W, Dorken B, Gilks W, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK (Eds): Leucocyte Typing IV. Oxford·University·Press,·Oxford. 1989; 1‑1820. <·NLM·ID:·8914679·> | López-Cabrera M, Santis AG, Fernández-Ruiz E, Blacher R, Esch F, Sánchez-Mateos P, Sánchez-Madrid F: Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C‑type animal lectin superfamily of signal‑transmitting receptors. J·Exp·Med. 1993·Aug·1; 178(2):537‑47. <·PMID:·8340758·> | Nielsen SD, Afzelius P, Ersbøll AK, Nielsen JO, Hansen JE: Expression of the activation antigen CD69 predicts functionality of in vitro expanded peripheral blood mononuclear cells (PBMC) from healthy donors and HIV‑infected patients. Clin·Exp·Immunol. 1998·Oct; 114(1):66‑72. <·PMID:·9764605·> | Drbal K, Moertelmaier M, Holzhauser C, Muhammad A, Fuertbauer E, Howorka S, Hinterberger M, Stockinger H, Schütz GJ: Single‑molecule microscopy reveals heterogeneous dynamics of lipid raft components upon TCR engagement. Int·Immunol. 2007·May; 19(5):675‑84. <·PMID:·17446208·> | Tomescu C, Chehimi J, Maino VC, Montaner LJ: NK cell lysis of HIV‑1‑infected autologous CD4 primary T cells: requirement for IFN‑mediated NK activation by plasmacytoid dendritic cells. J·Immunol. 2007·Aug·15; 179(4):2097‑104. <·PMID:·17675468·> | Konjević G, Jović V, Vuletić A, Radulović S, Jelić S, Spuzić I: CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma. Eur·J·Clin·Invest. 2007·Nov; 37(11):887‑96. <·PMID:·17973783·> | Pitsios C, Dimitrakopoulou A, Tsalimalma K, Kordossis T, Choremi-Papadopoulou H: Expression of CD69 on T‑cell subsets in HIV‑1 disease. Scand·J·Clin·Lab·Invest. 2008; 68(3):233‑41. <·PMID:·17917998·> | Hrdinka M, Dráber P, Stepánek O, Ormsby T, Otáhal P, Angelisová P, Brdicka T, Paces J, Horejsí V, Drbal K: PRR7 is a transmembrane adaptor protein expressed in activated T cells involved in regulation of T cell receptor signaling and apoptosis. J·Biol·Chem. 2011·Jun·3; 286(22):19617‑29. <·PMID:·21460222·>